TWI910256B - 使用經炔取代之喹唑啉衍生物類以治療癌症之方法 - Google Patents

使用經炔取代之喹唑啉衍生物類以治療癌症之方法

Info

Publication number
TWI910256B
TWI910256B TW110140833A TW110140833A TWI910256B TW I910256 B TWI910256 B TW I910256B TW 110140833 A TW110140833 A TW 110140833A TW 110140833 A TW110140833 A TW 110140833A TW I910256 B TWI910256 B TW I910256B
Authority
TW
Taiwan
Prior art keywords
leu
approximately
compound
egfr
pro
Prior art date
Application number
TW110140833A
Other languages
English (en)
Chinese (zh)
Other versions
TW202235083A (zh
Inventor
伊莉莎白 巴克
馬修 歐康納
達琳 羅曼許克
泰安 林
亞歷山大 弗洛爾
盧卡 亞歷斯塔
伊沃娜 羅納
馬修 盧卡斯
克里斯 羅伯茲
喬治歐 歐塔維尼
雪莉 史密斯
奈吉爾 瓦特斯
大衛 艾普斯坦
Original Assignee
美商黑鑽醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商黑鑽醫療公司 filed Critical 美商黑鑽醫療公司
Publication of TW202235083A publication Critical patent/TW202235083A/zh
Application granted granted Critical
Publication of TWI910256B publication Critical patent/TWI910256B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW110140833A 2020-11-02 2021-11-02 使用經炔取代之喹唑啉衍生物類以治療癌症之方法 TWI910256B (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US202063108645P 2020-11-02 2020-11-02
US63/108,645 2020-11-02
US202163166045P 2021-03-25 2021-03-25
US63/166,045 2021-03-25
US202163190067P 2021-05-18 2021-05-18
US63/190,067 2021-05-18
US202163218717P 2021-07-06 2021-07-06
US63/218,717 2021-07-06
US202163237782P 2021-08-27 2021-08-27
US63/237,782 2021-08-27
US202163244540P 2021-09-15 2021-09-15
US63/244,540 2021-09-15

Publications (2)

Publication Number Publication Date
TW202235083A TW202235083A (zh) 2022-09-16
TWI910256B true TWI910256B (zh) 2026-01-01

Family

ID=78819639

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110140833A TWI910256B (zh) 2020-11-02 2021-11-02 使用經炔取代之喹唑啉衍生物類以治療癌症之方法

Country Status (10)

Country Link
US (1) US20240075042A1 (https=)
EP (1) EP4236954A1 (https=)
JP (1) JP2023548055A (https=)
KR (1) KR20230093429A (https=)
AU (1) AU2021368798A1 (https=)
CA (1) CA3195473A1 (https=)
IL (1) IL302329A (https=)
MX (1) MX2023004998A (https=)
TW (1) TWI910256B (https=)
WO (1) WO2022094464A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328598A1 (en) 2019-08-15 2022-03-03 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
CA3231697A1 (en) * 2021-09-21 2023-03-30 Black Diamond Therapeutics, Inc. Polymorphs as erbb inhibitors
WO2025038731A1 (en) * 2023-08-15 2025-02-20 Black Diamond Therapeutics, Inc. Method of treating cancers with alkyne substituted quinazoline derivatives
WO2025128831A1 (en) * 2023-12-13 2025-06-19 Black Diamond Therapeutics, Inc. Combinations comprising alkyne substituted quinazoline derivatives and their use in the treatment of cancer
WO2025137421A1 (en) * 2023-12-21 2025-06-26 Black Diamond Therapeutics, Inc. Compositions comprising alkyne substituted quinazoline derivatives and related uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021030711A1 (en) * 2019-08-15 2021-02-18 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122058A2 (en) * 2011-03-04 2012-09-13 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
US20180193274A1 (en) * 2014-12-24 2018-07-12 Principia Biopharma Inc. Compositions for ileo-jejunal drug delivery
JP2022502495A (ja) * 2018-09-25 2022-01-11 ブラック ダイアモンド セラピューティクス，インコーポレイティド チロシンキナーゼ阻害剤としてのキナゾリン誘導体、組成物、それらの作製方法、およびそれらの使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021030711A1 (en) * 2019-08-15 2021-02-18 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds

Also Published As

Publication number Publication date
IL302329A (en) 2023-06-01
AU2021368798A9 (en) 2023-07-06
KR20230093429A (ko) 2023-06-27
MX2023004998A (es) 2023-05-12
EP4236954A1 (en) 2023-09-06
WO2022094464A1 (en) 2022-05-05
US20240075042A1 (en) 2024-03-07
CA3195473A1 (en) 2022-05-05
JP2023548055A (ja) 2023-11-15
AU2021368798A1 (en) 2023-05-18
TW202235083A (zh) 2022-09-16

Similar Documents

Publication Publication Date Title
TWI910256B (zh) 使用經炔取代之喹唑啉衍生物類以治療癌症之方法
JP5778735B2 (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して耐性を獲得した疾患を治療するためのピリミジン誘導体の使用
WO2023140329A1 (ja) がんの治療または予防用医薬
TW202128174A (zh) 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
CN113164776A (zh) 酪氨酸激酶抑制剂组合物、其制备方法和使用方法
WO2025038731A1 (en) Method of treating cancers with alkyne substituted quinazoline derivatives
CN116710096A (zh) 用炔取代的喹唑啉衍生物治疗癌症的方法
TW202339767A (zh) 螺環芳基磷氧化物與抗ｅｇｆｒ抗體的聯用藥物組合物及其用途
CN112203675A (zh) 用于改善虚弱和衰老的方法
US20230321087A1 (en) Fgfr inhibitor combination therapies
JP2021501160A (ja) 血液がんおよび固形がんの処置のためのカルシウム放出活性化カルシウムチャネルモジュレーター
KR20260053328A (ko) 알킨 치환된 퀴나졸린 유도체를 이용한 암 치료 방법
EP4534085A1 (en) Compounds for use in methods of treating cancer
TWI623315B (zh) ３－［（３－｛［４－（４－嗎啉基甲基）－１ｈ－吡咯－２－基］亞甲基｝－２－側氧基－２，３－二氫－１ｈ－吲哚－５－基）甲基］－１，３－噻唑啶－２，４－二酮及ｅｇｆｒ ｔｙｒ激酶抑制劑之新穎結合物
WO2024015506A1 (en) Methods of treating estrogen receptor-mediated disorders
WO2024254298A1 (en) A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
WO2024254266A1 (en) A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
KR20250171308A (ko) 베타-카테닌 길항제의 투여 및 사용 방법
TW201217341A (en) Receptor-type kinase modulator and methods of treating polycystic kidney disease
US20240207301A1 (en) Pharmaceutical composition and anti-tumor agent for tumor having decreased function of at least one of bap1 or pbrm1
CN121941699A (zh) 表皮生长因子受体抑制剂
EA052711B1 (ru) Лечение рака
EA051616B1 (ru) Лечение рака